An open-label, flexible-dose study of memantine in major depressive disorder - PubMed (original) (raw)
Clinical Trial
. 2007 May-Jun;30(3):136-44.
doi: 10.1097/WNF.0b013e3180314ae7.
Affiliations
- PMID: 17545748
- DOI: 10.1097/WNF.0b013e3180314ae7
Clinical Trial
An open-label, flexible-dose study of memantine in major depressive disorder
James M Ferguson et al. Clin Neuropharmacol. 2007 May-Jun.
Abstract
Objective: To assess the efficacy and safety of flexible-dose memantine in patients with major depressive disorder (MDD).
Methods: In this 12-week, single-center, open-label study, 8 patients with MDD were titrated for 4 weeks to 20 mg/d memantine. Nonresponsive patients were titrated to 30 mg/d (at week 8) or 40 mg/d (at week 10), provided that no dose-limiting adverse events were observed. Outcome measures were the Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Depression Rating Scale, the Clinical Global Impression-Severity of Illness and the Clinical Global Impression-Improvement Scales, the Patient Global Evaluation, and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Major Depressive Episode Checklist. Tolerability and safety assessments were performed throughout the trial.
Results: The safety population comprised 8 outpatients with a mean (SD) baseline MADRS score of 31.9 (4.45), indicative of severe depression. Seven subjects completed the study. All patients attained the target dose of 20 mg/d; 3 patients were titrated to 30 mg/d after week 8, and 2 patients were titrated to 40 mg/d after week 10. The mean dosage across all weeks was 18.1 mg. Patients improved on all efficacy measures within 1 week of treatment initiation. The mean improvement peaked at week 8 and was maintained through week 12 (MADRS, 18.5 [10.3]; last-observation-carried-forward). All memantine doses were well tolerated.
Conclusions: Memantine demonstrated early-onset efficacy in patients with MDD. The treatment was well tolerated. This study suggests that double-blind, placebo-controlled studies of memantine in depression are merited.
Similar articles
- Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV. Yevtushenko VY, et al. Clin Ther. 2007 Nov;29(11):2319-32. doi: 10.1016/j.clinthera.2007.11.014. Clin Ther. 2007. PMID: 18158074 Clinical Trial. - Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP. Wohlreich MM, et al. Depress Anxiety. 2007;24(1):41-52. doi: 10.1002/da.20209. Depress Anxiety. 2007. PMID: 16845641 Clinical Trial. - Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR; BOLDER II Study Group. Thase ME, et al. J Clin Psychopharmacol. 2006 Dec;26(6):600-9. doi: 10.1097/01.jcp.0000248603.76231.b7. J Clin Psychopharmacol. 2006. PMID: 17110817 Clinical Trial. - Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ. Shelton RC, et al. Int J Clin Pract. 2007 Aug;61(8):1337-48. doi: 10.1111/j.1742-1241.2007.01444.x. Int J Clin Pract. 2007. PMID: 17627710 Review. - [Diagnosis and severity assessment of patients with depression].
Terao T. Terao T. Nihon Rinsho. 2007 Sep;65(9):1614-8. Nihon Rinsho. 2007. PMID: 17876983 Review. Japanese.
Cited by
- Bridging rapid and sustained antidepressant effects of ketamine.
Kim JW, Suzuki K, Kavalali ET, Monteggia LM. Kim JW, et al. Trends Mol Med. 2023 May;29(5):364-375. doi: 10.1016/j.molmed.2023.02.003. Epub 2023 Mar 10. Trends Mol Med. 2023. PMID: 36907686 Free PMC article. Review. - A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints.
Lavretsky H, Laird KT, Krause-Sorio B, Heimberg BF, Yeargin J, Grzenda A, Wu P, Thana-Udom K, Ercoli LM, Siddarth P. Lavretsky H, et al. Am J Geriatr Psychiatry. 2020 Feb;28(2):178-190. doi: 10.1016/j.jagp.2019.08.011. Epub 2019 Aug 22. Am J Geriatr Psychiatry. 2020. PMID: 31519517 Free PMC article. Clinical Trial. - Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder.
Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang YS, Wang LJ, Lee IH, Yeh TL, Yang YK, Lu RB, Hong JS. Lee SY, et al. J Psychiatr Res. 2013 Oct;47(10):1343-8. doi: 10.1016/j.jpsychires.2013.06.017. Epub 2013 Jul 18. J Psychiatr Res. 2013. PMID: 23870798 Free PMC article. Clinical Trial. - A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life.
Strzelecki D, Tabaszewska A, Barszcz Z, Józefowicz O, Kropiwnicki P, Rabe-Jabłońska J. Strzelecki D, et al. Psychiatry Investig. 2013 Dec;10(4):421-4. doi: 10.4306/pi.2013.10.4.421. Epub 2013 Dec 16. Psychiatry Investig. 2013. PMID: 24474993 Free PMC article. - Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder.
Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang YS, Wang LJ, Lee IH, Wang TY, Yeh TL, Yang YK, Hong JS, Lu RB. Lee SY, et al. PLoS One. 2013 Jun 27;8(6):e66847. doi: 10.1371/journal.pone.0066847. Print 2013. PLoS One. 2013. PMID: 23826157 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources